CN100398142C - Traditional Chinese medicine composition for treating arthritis and preparing method thereof - Google Patents
Traditional Chinese medicine composition for treating arthritis and preparing method thereof Download PDFInfo
- Publication number
- CN100398142C CN100398142C CNB2005101264351A CN200510126435A CN100398142C CN 100398142 C CN100398142 C CN 100398142C CN B2005101264351 A CNB2005101264351 A CN B2005101264351A CN 200510126435 A CN200510126435 A CN 200510126435A CN 100398142 C CN100398142 C CN 100398142C
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- radix
- rhizoma
- radix astragali
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a traditional Chinese medicine composition for treating arthritis and a preparing method thereof. The traditional Chinese medicine composition has effective components prepared from frankincense, myrrh, safflower, turmeric, clematis root, cyathula root, nutagrass flatsedge rhizome, chuanxiong rhizome, astragalus root, red sage root and Chinese angelica are raw materials. The traditional Chinese medicine composition can be prepared into general medicaments in pharmacy, such as granules, tablets, capsules, etc. The traditional Chinese medicine composition has the functions of activating blood circulation, dissipating blood stasis, dredging channels and relieving pain, and can be used for treating rheumarthritis, rheumatoid arthritis, osteoarthrosis, gout or ankylosing spondylitis.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition, this Chinese medicine composition has the effect of blood circulation promoting and blood stasis dispelling, dredging collateral to stop pain, can be used for treating the Chinese medicine composition of rheumatic arthritis or rheumatoid arthritis or osseous arthritis or gout or ankylosing spondylitis, the invention still further relates to the preparation method of this Chinese medicine composition.
Background technology
Motherland's medical science is thought, the obstruction of collaterals by blood stasis disease in the arthromyodynia, how because of arthromyodynia with the passing of time, pathogen is gone into network, due to the meridian stasis resistance.Main clinical manifestation is: muscle, arthralgia are violent, are sensation of pricking more; Or for a long time pain endlessly, or pain in fixed position, tenderness, local swelling can have scleroma or ecchymosis or dim complexion, scaly dry skin first mistake is not damp, purplish tongue has ecchymosis, thready and hesitant pulse.Obstruction of collaterals by blood stasis diseases such as the rheumatoid arthritis of Western medicine diagnose, rheumatic arthritis, osteoarthritis, ankylosing spondylitis, gout.At present, the medicine of various these type of diseases of treatment is arranged on the market, but effect and not obvious.
In view of the medicine and the method for the treatment of arthritis that does not have better curative effect at present, thus a kind of good effect of demand still, taking convenience, the Chinese medicine for oral administration that side effect is little.This Chinese medicine composition is through animal experiment and clinical verification for many years, prove have blood circulation promoting and blood stasis dispelling, the dredging collateral to stop pain effect, the effect for the treatment of rheumatic arthritis or rheumatoid arthritis or osseous arthritis, gout or ankylosing spondylitis is arranged.
Summary of the invention
Purpose of the present invention just provides a kind of Chinese medicine composition with blood circulation promoting and blood stasis dispelling, dredging collateral to stop pain effect, can be used for treating rheumatic arthritis or rheumatoid arthritis or osseous arthritis or gout or ankylosing spondylitis.
Another object of the present invention just provides the preparation method of this Chinese medicine composition.
Motherland's medical science is thought, the obstruction of collaterals by blood stasis disease in the arthromyodynia, how because of arthromyodynia with the passing of time, pathogen is gone into network, due to the meridian stasis resistance.Main clinical manifestation is: muscle, arthralgia are violent, are sensation of pricking more; Or for a long time pain endlessly, or pain in fixed position, tenderness, local swelling can have scleroma or ecchymosis or dim complexion, scaly dry skin first mistake is not damp, purplish tongue has ecchymosis, therefore thready and hesitant pulse determines that the rule of treatment is blood circulation promoting and blood stasis dispelling, dredging collateral to stop pain.The effective ingredient of the present composition is exactly under the guidance of this treatment rule, selects for use following Chinese crude drug combined preparation to form.
The preparation raw material and the weight ratio thereof of Chinese medicine composition effective ingredient of the present invention are: Olibanum 3-12, Myrrha 3-11, Flos Carthami 5-18, Rhizoma Curcumae Longae 4-18, Radix Clematidis 5-25, Radix Cyathulae 5-25, Rhizoma Cyperi 4-20, Rhizoma Chuanxiong 5-25, Radix Astragali 8-25, Radix Salviae Miltiorrhizae 10-30, Radix Angelicae Sinensis 5-18.
Preferred weight proportion is: Olibanum 3-9, Myrrha 3-9, Flos Carthami 5-15, Rhizoma Curcumae Longae 7-14, Radix Clematidis 12-18, Radix Cyathulae 8-22, Rhizoma Cyperi 8-16, Rhizoma Chuanxiong 7-22, Radix Astragali 11-19, Radix Salviae Miltiorrhizae 15-25, Radix Angelicae Sinensis 6-15.
Olibanum, Myrrha, Rhizoma Cyperi and the Radix Astragali can be crude drug or its processed product in the above-mentioned raw materials, as Olibanum (processed), Myrrha (processed), Rhizoma Cyperi (processed), Radix Astragali (processed).
The preparation of Chinese medicine composition of the present invention can be that described raw material of Chinese medicine is pulverized the back decocting, filters, and obtains the water extract of above-mentioned raw materials, is prepared into various dosage forms with it and/or with mixing acceptable accessories again.
Chinese medicine composition of the present invention be preferably as follows preparation: the Radix Salviae Miltiorrhizae of getting Radix Cyathulae and 20-60%, the 20-60% Radix Astragali is pulverized, cross the 100-200 mesh sieve, get residue Radix Salviae Miltiorrhizae, the Radix Astragali and all the other medical materials, decoct with water 2-3 time, collecting decoction filters, the clear paste that filtrate is concentrated into relative density 1.1-1.4 (50 ℃) again with above-mentioned medicinal powder and/or and mixing acceptable accessories.
More preferably being prepared as follows of Chinese medicine composition of the present invention: get Rhizoma Chuanxiong, Rhizoma Cyperi, Rhizoma Curcumae Longae extraction volatile oil; Getting all the other 8 flavor medical materials decocts with water 2-3 time; Merge whole extracting solution, filter, be concentrated into the fluid extract that relative density is 1.08-1.12, add 2-3 times of weight ethanol and stir evenly, leave standstill, get supernatant, reclaim ethanol, be concentrated into the clear paste of relative density 1.1-1.4, with itself and/or with pharmaceutics on acceptable auxiliary granulate, drying adds volatile oil, mixing.
Chinese medicine composition of the present invention can be made various common formulations together with acceptable auxiliary on its effective ingredient and/or the pharmaceutics, as tablet, capsule or granule and other pharmaceutically acceptable dosage forms.
Acceptable accessories of the present invention includes but not limited to: starch, dextrin, Icing Sugar, low-substituted hydroxypropyl cellulose, carboxymethyl starch sodium, lactose, magnesium stearate, differential silica gel, Pulvis Talci etc.
Chinese medicine composition of the present invention is through pharmacodynamics and clinical confirmation, Chinese medicine composition of the present invention has blood circulation promoting and blood stasis dispelling, dredging collateral to stop pain effect really, and rheumatic arthritis or rheumatoid arthritis or osseous arthritis or gout or ankylosing spondylitis effect are remarkable for treating.
The specific embodiment
Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment only to be used to the present invention is described and be not used in and limit the scope of the invention.
Embodiment 1: the preparation of tablet of the present invention
Take by weighing following raw materials in weight: Olibanum 3g, Myrrha 3g, Flos Carthami 18g, Rhizoma Curcumae Longae 18g, Radix Clematidis 5g, Radix Cyathulae 5g, Rhizoma Cyperi 20g, Rhizoma Chuanxiong 25g, Radix Astragali 25g, Radix Salviae Miltiorrhizae 10g, Radix Angelicae Sinensis 5g.
Get Radix Cyathulae, 6g Radix Salviae Miltiorrhizae and the 5g Radix Astragali and pulverize, cross 200 mesh sieves, get residue Radix Salviae Miltiorrhizae, the Radix Astragali and all the other medical materials, decoct with water 3 times, collecting decoction filters, and filtrate is concentrated into the clear paste of relative density 1.4 (50 ℃), add Radix Cyathulae, the Radix Astragali, Radix Salviae Miltiorrhizae fine powder, granulate, drying adds 0.3% magnesium stearate again, tabletting promptly gets tablet of the present invention.
Embodiment 2: the preparation of granule of the present invention
Take by weighing following raw materials in weight: Olibanum (processed) 6g, Myrrha 6g, Flos Carthami 10g, Rhizoma Curcumae Longae 10g, Radix Clematidis 1 5g, Radix Cyathulae 15g, Rhizoma Cyperi 12g, Rhizoma Chuanxiong 15g, Radix Astragali 15g, Radix Salviae Miltiorrhizae 20g, Radix Angelicae Sinensis 10g.
Get Rhizoma Chuanxiong, Rhizoma Cyperi, Rhizoma Curcumae Longae extraction volatile oil; Getting all the other 8 flavor medical materials decocts with water 2 times; Merge whole extracting solution, filter, be concentrated into relative density and be 1.12 fluid extract, add 2 times of weight ethanol and stir evenly, leave standstill, get supernatant, reclaim ethanol, be concentrated into the clear paste of relative density 1.1, add dextrin, starch, granulate, dry, cross the 10-65 mesh sieve, add the volatile oil mixing, promptly get granule of the present invention.
Embodiment 3: the preparation of capsule of the present invention
Take by weighing following raw materials in weight: Olibanum 9g, Myrrha 9g, Flos Carthami 15g, Rhizoma Curcumae Longae 12g, Radix Clematidis 12g, Radix Cyathulae 8g, Rhizoma Cyperi (processed) 8g, Rhizoma Chuanxiong 22g, Radix Astragali 19g, Radix Salviae Miltiorrhizae 12g, Radix Angelicae Sinensis 6g.
Olibanum, Myrrha, Flos Carthami, Rhizoma Curcumae Longae, Radix Clematidis, Radix Cyathulae, Rhizoma Cyperi, Rhizoma Chuanxiong, the Radix Astragali, Radix Salviae Miltiorrhizae, Radix Angelicae Sinensis water are decocted 2 times, merge, filter, filtrate is concentrated into the clear paste of relative density 1.4 (50 ℃), make granule with dextrin, starch, drying is crossed 40 mesh sieves, encapsulated, promptly get capsule of the present invention.
Embodiment 4: the preparation of capsule of the present invention
Take by weighing following raw materials in weight: Olibanum 8g, Myrrha (processed) 7g, Flos Carthami 12g, Rhizoma Curcumae Longae 11g, Radix Clematidis 13g, Radix Cyathulae 18g, Rhizoma Cyperi 14g, Rhizoma Chuanxiong 19g, Radix Astragali 12g, Radix Salviae Miltiorrhizae 14g, Radix Angelicae Sinensis 12g.
Get Radix Cyathulae and 2.8g Radix Salviae Miltiorrhizae, the 7.2g Radix Astragali is pulverized, and crosses 100 mesh sieves, get residue Radix Salviae Miltiorrhizae, the Radix Astragali and all the other medical materials, decoct with water collecting decoction 2 times, filter, filtrate is concentrated into the clear paste of relative density 1.1 (50 ℃), adds Radix Salviae Miltiorrhizae, Radix Astragali fine powder, adds starch again and granulates, dry, cross 20 mesh sieves, encapsulated, promptly get capsule of the present invention.
Embodiment 5: the preparation of tablet of the present invention
Take by weighing following raw materials in weight: Olibanum (processed) 8g, Myrrha 4g, Flos Carthami 12g, Rhizoma Curcumae Longae 11g, Radix Clematidis 13g, Radix Cyathulae 11g, Rhizoma Cyperi 14g, Rhizoma Chuanxiong 19g, Radix Astragali (processed) 17g, Radix Salviae Miltiorrhizae 28g, Radix Angelicae Sinensis 12g.
Get Rhizoma Chuanxiong, Rhizoma Cyperi, Rhizoma Curcumae Longae extraction volatile oil; Getting all the other 8 flavor medical materials decocts with water 3 times; Merge whole extracting solution, filter, be concentrated into relative density and be 1.08 fluid extract, add 3 times of weight ethanol and stir evenly, leave standstill, get supernatant, reclaim ethanol, be concentrated into the clear paste of relative density 1.4, add starch, dextrin granulation, add 0.3% magnesium stearate again, tabletting, coating promptly gets tablet of the present invention.
Embodiment 6: the preparation of tablet of the present invention
Take by weighing following raw materials in weight Olibanum 6g, Myrrha (processed) 4g, Flos Carthami 7g, Rhizoma Curcumae Longae 10g, Radix Clematidis 13g, Radix Cyathulae 18g, Rhizoma Cyperi 13g, Rhizoma Chuanxiong 15g, Radix Astragali 14g, Radix Salviae Miltiorrhizae 20g, Radix Angelicae Sinensis 8g.
Preparation method is with embodiment 1.
Below set forth the effect of this Chinese medicine composition by test.
Experiment material: positive control drug is a FENGSHIBIKANG JIAONANG, and Hua Jia pharmaceutcal corporation, Ltd in Jilin produces, lot number 99010403, specification 0.3g/ grain.
Laboratory animal: rat Wistar kind, white mice HM kind, Liaoning Province medical industry academy animal housing provides, the quality certification number: No. 003, the real moving word of the Liao Dynasty.
Experimental example 1: Chinese medicine composition on Carrageenan of the present invention causes the influence of rat paw edema
Get 40 of male white rats, body weight 120-150g is divided into 4 groups at random, 10 every group, irritates the stomach embodiment of the invention 2 gained granule 4.64g/kg and 2.32g/kg (by the crude drug amount) respectively; Positive control drug FENGSHIBIKANG JIAONANG 0.16 g/kg; Matched group waits the capacity normal saline.All every day gastric infusion once, 1 week of successive administration, last administration 30 minutes, 1% carrageenin 0.05ml causes inflammation in rat foot subcutaneous injection, measure administration before, 1,2,3,4,6 hour right back ankle joint Zhou Jing after the administration.Before causing inflammation with each rat, the difference of back ankle joint Zhou Jing is the swelling degree, calculates and organizes swelling degree average and standard deviation fully, and relatively each group difference the results are shown in Table 1.As can be seen, rat paw edema has obvious inhibitory action due to the Chinese medicine composition on Carrageenan of the present invention, points out it to have antiinflammatory action.
The influence of rat paw edema due to the table 1 Chinese medicine composition on Carrageenan of the present invention
*, P＜0.05
*, compare with matched group P＜0.01
Experimental example 2: Chinese medicine composition of the present invention is to the influence of granuloma induced by implantation of cotton pellets
Get 32 of male rats, body weight 140-170g, be divided into 4 groups at random, every group 8, through abdominal incision, (each cotton balls weighs 50 ± 1mg) autoclavings with two aseptic cotton balls under the sterile working, each only adds ciprofloxacin ether light anaesthesia 1mg/0.1ml/, 50 ℃ of stove-dryings, it is subcutaneous to implant rat both sides groin respectively, and postoperative began gastric infusion 4.64g/kg and 2.32g/kg (by the crude drug amount) same day; Positive control drug FENGSHIBIKANG JIAONANG 0.16 g/kg; Matched group waits the capacity normal saline.Once a day, continuous 8 days, the dislocation of animal cervical vertebra was put to death in last administration 1 hour, gets cotton balls, and it is roasting to constant weight to put 60 ℃ of baking boxs, weighs.Deduct the raw cotton ball weight, be granuloma and weigh.Respectively organize the granuloma weight differential, the results are shown in Table 2.As can be seen, Chinese medicine composition of the present invention can obviously alleviate granuloma weight, and obvious antagonism connective tissue proliferation effect is arranged, with the same level of acting on of FENGSHIBIKANG JIAONANG.
Table 2 Chinese medicine composition of the present invention is to the influence of granuloma induced by implantation of cotton pellets
*, P＜0.05; Compare with matched group
Experimental example 3: Chinese medicine composition of the present invention is to the influence of abdominal cavity capillary permeability
40 of male white mouses, body weight 19-21g is divided into 4 groups at random, 10 every group, irritates the stomach embodiment of the invention 4 gained capsule 9.46g/kg and 4.23g/kg (by the crude drug amount) respectively; Positive control drug FENGSHIBIKANG JIAONANG 0.33 g/kg; Matched group waits the capacity normal saline.Every day gastric infusion once, successive administration 9 days, after the last administration 1 hour, the blue 0.1ml/10g of tail vein injection 1% ivens, the abdominal cavity only injects 0.7% glacial acetic acid 0.2ml/ immediately, with the animal sacrificed by decapitation, lumbar injection 5ml normal saline is drawn peritoneal fluid after 20 minutes, centrifugal 15 minutes, survey trap in the 590nm place, relatively each group difference the results are shown in Table 3.Chinese medicine composition of the present invention strengthens the abdominal cavity capillary permeability due to the glacial acetic acid obvious inhibitory action.
Table 3 Chinese medicine composition of the present invention is to the influence of abdominal cavity capillary permeability
*, P＜0.05; Compare with matched group
Experimental example 4: Chinese medicine composition Dichlorodiphenyl Acetate of the present invention causes the influence of pain
40 of male and female white mice, body weight 18-22g is divided into 4 groups at random, 10 every group, irritates the stomach embodiment of the invention 3 gained capsule 9.46g/kg and 4.23g/kg (by the crude drug amount) respectively; Positive control drug FENGSHIBIKANG JIAONANG 0.33 g/kg; Matched group waits the capacity normal saline.Every day gastric infusion once, successive administration 7 days, in 40 minutes each Mus lumbar injection 0.3% glacial acetic acid 0.2ml/ of last administration only, immediately in the opening entry 20 minutes each mice turn round the body number of times, the results are shown in Table 4.As can be seen, what Chinese medicine composition of the present invention can obviously reduce acetic acid induced mice abdominal pain turns round the body number of times, and obvious analgesic activity is arranged.
Table 4 Chinese medicine composition of the present invention is to the influence of mice acetic acid twisting reaction
*, P＜0.05; Compare with matched group
Experimental example 5: Chinese medicine composition of the present invention is to the influence in Mus tail bleeding time
Select 1 8-22g white mice for use, the male and female dual-purpose is divided into 4 groups at random, irritates the stomach embodiment of the invention 6 gained tablet 9.46g/kg and 4.23g/kg (by the crude drug amount) respectively; Positive control drug FENGSHIBIKANG JIAONANG 0.33 g/kg; Matched group waits the capacity normal saline.Continuous irrigation stomach seven days, after the last administration 30 minutes, cross-section in mouse tail point 0.5 centimeters respectively, blood flows out the back timing voluntarily, inhales to dehematize with filter paper every 15 seconds and drips once, stops naturally until blood, calculate the bleeding time, gained data and matched group carry out significance test.As can be seen, Chinese medicine composition 9.46 g/kg of the present invention can prolong the mouse tail bleeding time, the effect of invigorating blood circulation.
Table 5 granule of the present invention is to the influence in mouse tail bleeding time
*, P＜0.05; Compare with matched group
Experimental example 6: Chinese medicine composition of the present invention is to the influence of rat assist agent arthritis
60 of rats, male and female half and half are divided 6 groups at random by body weight. and first group of 10 rat is the normal control group, in its right back sufficient sole of the foot intradermal injection normal saline 0.1ml/ only; The complete freund adjuvant 0.1ml/ of the right back sufficient sole of the foot intradermal injection of all the other rats only, before the adjuvant injection and the 3h of injection back, 18h measured respectively and respectively to organize sufficient volume below the right ankle of the rat joint in 3,6,9,12,15,18,21 days.And cause the secondary reactions of the 10th day opening entry animal in scorching back in adjuvant, did the sxemiquantitative record (0 minute: do not have red and swollen with 5 grades of point systems; 1 minute: little toe joint was swollen slightly; 2 minutes: toe joint and pedal swelling; 3 minutes: the following foot swelling of ankle joint; 4 minutes: comprise the whole sufficient pawl swelling of ankle joint), per 3 days records are once.The 6th day rat begins administration behind the Yu Zhiyan, wherein, first and second group rat oral gavage distilled water 10ml/kg, the the 3rd to the five group of rat oral gavage embodiment of the invention 2 gained granules 1.66,2.32 and 4.64 g/kg (by the crude drug amount), (Baiyunshan Qingzheng Pharmaceutical Co., Ltd provides the 6th group of rat oral gavage ZHENGQINGFENGTONGNING PIAN, lot number: 9903132) 4.64 g/kg.1 time/day, continuous 7 days, inject administration 7 days in the same way again in the 19th day in adjuvant, experimental session is observed the body weight of rat, and the situation of inflammatory reaction is estimated drug effect.
Inject complete freund adjuvant and can cause the direct inflammatory reaction of rat injection site, thereafter also can produce the inflammatory reaction of a series of secondary, comprise the swelling of non-injection acra, the reactions such as arthritis tuberosity that afterbody, ear occur, this series reaction of observed and recorded can be used for evaluate efficacy.
Attack the direct inflammatory reaction that causes the rat injection site for complete freund adjuvant: normal rat is more stable at experimental session foot volume, the just growth of follower body weight, and some becomes big sufficient volume.The rat foot begins swelling after injecting complete freund adjuvant, and with the prolongation of moulding time, the aggravation of the degree of swelling.After granule of the present invention was given rat oral gavage, the swelling that adjuvant is caused had certain inhibitory action.And strengthen with the dosage of medicine, (table 6) strengthened in the effect of adjuvant-induced arthritis.
Complete freund adjuvant is attacked the preventive effect that causes the inflammatory reaction of rat secondary: inject administration in the 6th to the 13 day in adjuvant, and during the administration and detect the secondary inflammatory reaction of rat after the administration, by table 7 data as can be seen: normal rat secondary reactions do not occur at experimental session.After injecting complete freund adjuvant, rat shows left foot swelling, left and right pawl swelling, tuberosity appears in afterbody, ear, injects in adjuvant and can see some secondary reactions signs on the tenth day, to adjuvant injection 13 days, it is fairly obvious that secondary reactions becomes, wherein the secondary reactions of model control group performance is more obvious, and Chinese medicine composition of the present invention causes that to adjuvant the generation of secondary reactions has certain inhibitory action (table 7) after giving rat oral gavage.
Table 6 Chinese medicine composition of the present invention is to the influence of adjuvant-induced arthritis
N=10, with the normal control group than #p＜0.01.With arthritis matched group ratio
*P＜0.05,
*P＜0.01.
Complete freund adjuvant is attacked the therapeutical effect that causes the inflammatory reaction of rat secondary: inject in adjuvant and began medication once more on the 19th day, and during the administration and detect the secondary inflammatory reaction of rat after the administration, by the 3rd to six column data of table 7 as can be seen: normal rat secondary reactions still do not occur at experimental session.Inject rat left side foot swelling behind the complete freund adjuvant, left and right pawl swelling, afterbody, ear secondary reactions such as tuberosity occurs and show more outstandingly.Wherein the secondary reactions of model control group performance is obvious, and after Chinese medicine composition of the present invention was given rat oral gavage, the secondary reactions that adjuvant is caused had remarkable inhibitory action (table 7).
Table 7 Chinese medicine composition of the present invention is to the influence of adjuvant arthritis rats secondary reactions
N=10 is with the model control group ratio
*P＜0.05.
**p＜0.01。
Claims (7)
1. Chinese medicine composition for the treatment of rheumatic arthritis, rheumatoid arthritis, osseous arthritis, gout or ankylosing spondylitis, it is made up of effective ingredient and/or acceptable accessories, and described effective ingredient is made by the following weight proportion raw material: Olibanum 3-12, Myrrha 3-11, Flos Carthami 5-18, Rhizoma Curcumae Longae 4-18, Radix Clematidis 5-25, Radix Cyathulae 5-25, Rhizoma Cyperi 4-20, Rhizoma Chuanxiong 5-25, Radix Astragali 8-25, Radix Salviae Miltiorrhizae 10-30, Radix Angelicae Sinensis 5-18.
2. Chinese medicine composition as claimed in claim 1 is characterized in that described effective ingredient made by the following weight proportion raw material: Olibanum 3-9, Myrrha 3-9, Flos Carthami 5-15, Rhizoma Curcumae Longae 7-14, Radix Clematidis 12-18, Radix Cyathulae 8-22, Rhizoma Cyperi 8-16, Rhizoma Chuanxiong 7-22, Radix Astragali 11-19, Radix Salviae Miltiorrhizae 15-25, Radix Angelicae Sinensis 6-15.
3. Chinese medicine composition as claimed in claim 1 is characterized in that described Olibanum is an Olibanum (processed); Described Myrrha is a Myrrha (processed); Described Rhizoma Cyperi is a Rhizoma Cyperi (processed); The described Radix Astragali is a Radix Astragali (processed).
4. as the arbitrary described Chinese medicine composition of claim 1-3, it is tablet, capsule or granule.
5. as the preparation method of the arbitrary described Chinese medicine composition of claim 1-3, it comprises pulverizes the back decocting with described raw material of Chinese medicine, filters, and obtains the water extract of above-mentioned raw materials, again with itself and/or and mixing acceptable accessories.
6. as the preparation method of the arbitrary described Chinese medicine composition of claim 1-3, it comprises that the Radix Astragali of the Radix Salviae Miltiorrhizae of getting Radix Cyathulae, 20-60% and 20-60% pulverizes, cross the 100-200 mesh sieve, get residue Radix Salviae Miltiorrhizae, the Radix Astragali and all the other medical materials, decoct with water 2-3 time, collecting decoction filters, the clear paste that filtrate is concentrated into relative density 1.1-1.4 again with above-mentioned medicinal powder and/or and mixing acceptable accessories.
7. as the preparation method of the arbitrary described Chinese medicine composition of claim 1-3, it comprises gets Rhizoma Chuanxiong, Rhizoma Cyperi, Rhizoma Curcumae Longae extraction volatile oil; Getting all the other 8 flavor medical materials decocts with water 2-3 time; Merge whole extracting solution, filter, be concentrated into the fluid extract that relative density is 1.08-1.12, add 2-3 times of weight ethanol and stir evenly, leave standstill, get supernatant, reclaim ethanol, be concentrated into the clear paste of relative density 1.1-1.4, with itself and/or with pharmaceutics on acceptable auxiliary granulate, drying adds volatile oil, mixing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101264351A CN100398142C (en) | 2005-12-09 | 2005-12-09 | Traditional Chinese medicine composition for treating arthritis and preparing method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101264351A CN100398142C (en) | 2005-12-09 | 2005-12-09 | Traditional Chinese medicine composition for treating arthritis and preparing method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1836725A CN1836725A (en) | 2006-09-27 |
| CN100398142C true CN100398142C (en) | 2008-07-02 |
Family
ID=37014319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005101264351A Active CN100398142C (en) | 2005-12-09 | 2005-12-09 | Traditional Chinese medicine composition for treating arthritis and preparing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100398142C (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101953926B (en) * | 2010-08-25 | 2011-11-16 | 邓兰芹 | Oral Chinese medicinal composition for treating gout |
| CN102847074B (en) * | 2012-09-28 | 2014-04-09 | 郑州中医骨伤病医院 | Blood stasis removing pill for treating ankylosing spondylitis |
| CN103690888B (en) * | 2013-12-19 | 2016-03-30 | 青岛市第三人民医院 | A kind of Chinese medicine water-honeyed pill and preparation method for the treatment of gout |
| CN104857101A (en) * | 2015-05-11 | 2015-08-26 | 何小平 | Health-care external-application ointment for treating rheumatic arthritis and preparation method of health-care external-application ointment |
| CN105287721A (en) * | 2015-08-11 | 2016-02-03 | 杭州市中医院 | Chinese herbal compound for treating arthritis, cataplasm preparation of Chinese herbal compound for treating arthritis and method for preparing cataplasm preparation |
| CN105169268A (en) * | 2015-09-29 | 2015-12-23 | 南京晶云化工有限公司 | Oral solution for treating arthritis |
| CN108853442A (en) * | 2018-10-09 | 2018-11-23 | 常逸宸 | A kind of Chinese medicine composition for treating gonitis |
| CN111375035B (en) * | 2018-12-29 | 2021-10-29 | 辽宁上药好护士药业（集团）有限公司 | Preparation and application of enteric-coated preparation for treating cervical spondylosis |
| CN113116862B (en) * | 2019-12-30 | 2022-05-27 | 辽宁上药好护士药业（集团）有限公司 | Blood stasis arthralgia micro-pill and preparation method and application thereof |
| CN113181322A (en) * | 2021-06-17 | 2021-07-30 | 广西汉方真宝药业有限公司 | Swelling-diminishing and pain-relieving ointment for gout |
| CN115814041B (en) * | 2022-12-26 | 2023-11-03 | 辽宁上药好护士药业（集团）有限公司 | A Chinese medicinal composition for treating headache, and its preparation method |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1236803A (en) * | 1999-06-10 | 1999-12-01 | 邓志福 | Dissolving process for preparing modified refractory asphalt |
| CN1411856A (en) * | 2002-09-27 | 2003-04-23 | 傅惠明 | Rheumatism display and treatment liquid |
-
2005
- 2005-12-09 CN CNB2005101264351A patent/CN100398142C/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1236803A (en) * | 1999-06-10 | 1999-12-01 | 邓志福 | Dissolving process for preparing modified refractory asphalt |
| CN1411856A (en) * | 2002-09-27 | 2003-04-23 | 傅惠明 | Rheumatism display and treatment liquid |
Non-Patent Citations (1)
| Title |
|---|
| 中华人民共和国卫生部药品标准中药成方制剂. 中华人民共和国卫生部药典委员会，188. 1998 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1836725A (en) | 2006-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100398142C (en) | Traditional Chinese medicine composition for treating arthritis and preparing method thereof | |
| CN100488552C (en) | Chinese medicine composition for treating arthritis or gout and preparing method thereof | |
| CN101933991B (en) | Analgesic and anti-inflammatory medicament and preparation method thereof | |
| CN101732668B (en) | Preparation method of Chinese medicinal composition for treating urinary system infection | |
| CN101167937A (en) | Traditional Chinese medicinal composition plaster for curing rheumatism or rheumatoid diseases and preparation method thereof | |
| CN102935133B (en) | Traditional Chinese medicine composition for treating rheumatic arthritis as well as preparation method and application thereof | |
| CN1931277B (en) | Osteoarthrosis treating Chinese medicine composition and its preparation process | |
| CN102657736B (en) | Medicament composition for treating rheumatoid arthritis and preparation method of medicament composition | |
| CN101254186A (en) | Medicament use of myricetin | |
| CN102145091B (en) | Traditional Chinese medicinal composition for eliminating wind and relieving heat and preparation method thereof | |
| CN100363043C (en) | Chinese traditional medicine composition for treating rheumatic or rheumatoid disease and preparation method thereof | |
| CN1954877B (en) | Chinese medicinal composite for treating ischemic necrosis of femoral head and its preparation method | |
| CN103536815A (en) | Traditional Chinese medicinal composition for treating hemorrhoids symptoms | |
| CN100534466C (en) | Preparation for treating arthritis and preparation method thereof | |
| CN106237181A (en) | A kind of Chinese medicine composition treating rheumatoid arthritis and capsule thereof and preparation method | |
| CN105250397A (en) | Spirulina traditional Chinese medicine composition | |
| CN101524447A (en) | Pharmaceutical composition for treating constipation and preparation process thereof | |
| CN101024029B (en) | Medicine for treating bony arthritis, rheumatism arthritis | |
| CN104436022A (en) | Hemsleya-macrosperma-containing traditional Chinese medicine composition for treating diabetes mellitus | |
| CN103251688B (en) | Chinese medicinal composition for treating arthritis and application thereof | |
| CN101966304A (en) | Medicament for freeing network vessels and activating blood and preparation method thereof | |
| CN103301380A (en) | Liver-soothing and qi-regulating traditional Chinese medicinal composition and preparation method thereof | |
| CN1861119B (en) | Traditional Chinese medicine for treating rheumatosis and its preparation method | |
| CN100411670C (en) | Medicine for treating tumor in upper digestive tract and its preparing method | |
| CN107149665B (en) | Traditional Chinese medicine for treating interstitial lung disease and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: LIAONING HAOHUSHI MEDICINE ( GROUP ) CO., LTD. Free format text: FORMER OWNER: BENXI TIANYIN PHARMACEUTICAL CO., LTD. Effective date: 20070803 Owner name: LIAONING HAOHUSHI PHARMACEUTICAL( GROUP ) CO., LT Free format text: FORMER OWNER: BENXI TIANYIN PHARMACEUTICAL CO., LTD. Effective date: 20070803 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20070803 Address after: 117201 Xin'an street, Huanren Town, Huanren Manchu Autonomous County, Liaoning Province Applicant after: Liaoning good nurse Pharmaceutical (Group) Co.,Ltd. Address before: 117004 medicine Park, Benxi economic and Technological Development Zone, Liaoning Applicant before: Benxi Tianyin Pharmaceutical Co.,Ltd. Effective date of registration: 20070803 Address after: 117201 Xin'an street, Huanren Town, Huanren Manchu Autonomous County, Liaoning Province Applicant after: LIAONING GOOD NURSE PHARMACEUT Address before: 117004 Benxi Liaoning economic and Technological Development Zone pharmaceutical Park Benxi Tian India Pharmaceutical Co., Ltd. Applicant before: Benxi Tianyin Pharmaceutical Co.,Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP03 | Change of name, title or address |
Address after: 117201, No. 6, Taishan Road, five female mountain Economic Development Zone, Huanren County, Liaoning, Benxi Patentee after: LIAONING HERBPEX PHARMACEUTICAL (GROUP) CO.,LTD. Address before: 117201 Xin'an street, Huanren Town, Huanren Manchu Autonomous County, Liaoning Province Patentee before: LIAONING GOOD NURSE PHARMACEUT |